TY - JOUR
T1 - Prognostic value of chromogranin A in chronic heart failure
T2 - Data from the GISSI-Heart Failure trial
AU - Røsjø, Helge
AU - Masson, Serge
AU - Latini, Roberto
AU - Flyvbjerg, Allan
AU - Milani, Valentina
AU - La Rovere, Maria Teresa
AU - Revera, Miriam
AU - Mezzani, Alessandro
AU - Tognoni, Gianni
AU - Tavazzi, Luigi
AU - Omland, Torbjørn
PY - 2010/6
Y1 - 2010/6
N2 - Aims To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). Methods and results Plasma CgA levels were measured at randomization and after 3 months in 1233 patients (median age 68 years, 80 male) with chronic, stable HF from the GISSI-HF trial. Circulating CgA levels were associated with several established risk markers in HF, including increased age, diabetes, reduced renal function, and heart rate variability. During a median follow-up of 3.9 years, 333 patients (27) died. By univariable analysis, plasma CgA levels at baseline were strongly associated with all-cause mortality during follow-up; 2nd vs. 1st tertile: HR 1.58 (1.17-2.11), P = 0.002; and 3rd vs. 1st tertile: HR 2.35 (1.78-3.10), P <0.0001. After adjustment for established risk factors of mortality, this association was attenuated and no longer significant. Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin did not significantly change plasma CgA concentration over 3 months. Conclusion Measurement of circulating CgA levels in patients with chronic, stable HF does not provide incremental prognostic information to that obtained from physical examination, routine biochemical analysis, and contemporary HF biomarkers.
AB - Aims To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). Methods and results Plasma CgA levels were measured at randomization and after 3 months in 1233 patients (median age 68 years, 80 male) with chronic, stable HF from the GISSI-HF trial. Circulating CgA levels were associated with several established risk markers in HF, including increased age, diabetes, reduced renal function, and heart rate variability. During a median follow-up of 3.9 years, 333 patients (27) died. By univariable analysis, plasma CgA levels at baseline were strongly associated with all-cause mortality during follow-up; 2nd vs. 1st tertile: HR 1.58 (1.17-2.11), P = 0.002; and 3rd vs. 1st tertile: HR 2.35 (1.78-3.10), P <0.0001. After adjustment for established risk factors of mortality, this association was attenuated and no longer significant. Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin did not significantly change plasma CgA concentration over 3 months. Conclusion Measurement of circulating CgA levels in patients with chronic, stable HF does not provide incremental prognostic information to that obtained from physical examination, routine biochemical analysis, and contemporary HF biomarkers.
KW - Biomarkers
KW - Chromogranin A
KW - GISSI-HF
KW - Heart failure
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=77952994790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952994790&partnerID=8YFLogxK
U2 - 10.1093/eurjhf/hfq055
DO - 10.1093/eurjhf/hfq055
M3 - Article
C2 - 20388648
AN - SCOPUS:77952994790
VL - 12
SP - 549
EP - 556
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 6
ER -